These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 26116791

  • 1. Poor efficacy of nucleic acid testing in identifying occult HBV infection and consequences for safety of blood supply in Italy.
    Spreafico M, Berzuini A, Foglieni B, Candotti D, Raffaele L, Guarnori I, Colli A, Maldini FF, Allain JP, Prati D.
    J Hepatol; 2015 Nov; 63(5):1068-76. PubMed ID: 26116791
    [Abstract] [Full Text] [Related]

  • 2. Blood donation screening for hepatitis B virus markers in the era of nucleic acid testing: are all tests of value?
    Stramer SL, Zou S, Notari EP, Foster GA, Krysztof DE, Musavi F, Dodd RY.
    Transfusion; 2012 Feb; 52(2):440-6. PubMed ID: 21810101
    [Abstract] [Full Text] [Related]

  • 3. Hepatitis B virus testing by minipool nucleic acid testing: does it improve blood safety?
    Stramer SL, Notari EP, Krysztof DE, Dodd RY.
    Transfusion; 2013 Oct; 53(10 Pt 2):2449-58. PubMed ID: 23607261
    [Abstract] [Full Text] [Related]

  • 4. Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors?
    Busch MP.
    Transfus Clin Biol; 2004 Feb; 11(1):26-32. PubMed ID: 14980546
    [Abstract] [Full Text] [Related]

  • 5. Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program.
    Satake M, Taira R, Yugi H, Hino S, Kanemitsu K, Ikeda H, Tadokoro K.
    Transfusion; 2007 Jul; 47(7):1197-205. PubMed ID: 17581154
    [Abstract] [Full Text] [Related]

  • 6. NAT for HBV and anti-HBc testing increase blood safety.
    Roth WK, Weber M, Petersen D, Drosten C, Buhr S, Sireis W, Weichert W, Hedges D, Seifried E.
    Transfusion; 2002 Jul; 42(7):869-75. PubMed ID: 12375659
    [Abstract] [Full Text] [Related]

  • 7. Blood donor screening in the Netherlands: Universal anti-HBc screening in combination with HBV nucleic acid amplification testing may allow discontinuation of hepatitis B virus antigen testing.
    van de Laar TJ, Hogema BM, Molenaar-de Backer MW, Marijt-van der Kreek T, Zaaijer HL.
    Transfusion; 2021 Jul; 61(7):2116-2124. PubMed ID: 33899233
    [Abstract] [Full Text] [Related]

  • 8. High Frequency Occult Hepatitis B Virus Infection Detected in Non-Resolved Donations Suggests the Requirement of Anti-HBc Test in Blood Donors in Southern China.
    Ye X, Zhao Y, Li R, Li T, Zheng X, Xiong W, Zeng J, Xu M, Chen L.
    Front Immunol; 2021 Jul; 12():699217. PubMed ID: 34394093
    [Abstract] [Full Text] [Related]

  • 9. Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: implications for future HBV screening policy.
    Kuhns MC, Kleinman SH, McNamara AL, Rawal B, Glynn S, Busch MP, REDS Study Group.
    Transfusion; 2004 Sep; 44(9):1332-9. PubMed ID: 15318857
    [Abstract] [Full Text] [Related]

  • 10. A pilot study for screening blood donors in Taiwan by nucleic acid amplification technology: detecting occult hepatitis B virus infections and closing the serologic window period for hepatitis C virus.
    Li L, Chen PJ, Chen MH, Chak KF, Lin KS, Tsai SJ.
    Transfusion; 2008 Jun; 48(6):1198-206. PubMed ID: 18422856
    [Abstract] [Full Text] [Related]

  • 11. Hepatitis B virus (HBV) DNA screening of blood donations in minipools with the COBAS AmpliScreen HBV test.
    Kleinman SH, Strong DM, Tegtmeier GG, Holland PV, Gorlin JB, Cousins C, Chiacchierini RP, Pietrelli LA.
    Transfusion; 2005 Aug; 45(8):1247-57. PubMed ID: 16078909
    [Abstract] [Full Text] [Related]

  • 12. Detection of occult hepatitis B and window period infection among blood donors by individual donation nucleic acid testing in a tertiary care center in South India.
    Keechilot CS, Shenoy V, Kumar A, Biswas L, Vijayrajratnam S, Dinesh K, Nair P.
    Pathog Glob Health; 2016 Aug; 110(7-8):287-291. PubMed ID: 27788631
    [Abstract] [Full Text] [Related]

  • 13. Cost-benefit analysis of serological and nucleic acid testing for hepatitis B virus in blood donors in southern China.
    Ye X, Xiong W, Xu X, Zeng J, Xie H, Li B, He B, Chen L, Mo Q.
    BMC Infect Dis; 2024 Sep 02; 24(1):909. PubMed ID: 39223540
    [Abstract] [Full Text] [Related]

  • 14. Enhanced detection of hepatitis B virus in Hong Kong blood donors after introduction of a more sensitive transcription-mediated amplification assay.
    Tsoi WC, Lelie N, Lin CK.
    Transfusion; 2013 Oct 02; 53(10 Pt 2):2477-88. PubMed ID: 23521050
    [Abstract] [Full Text] [Related]

  • 15. Residual risk of transfusion-transmitted hepatitis B virus (HBV) infection caused by blood components derived from donors with occult HBV infection in Japan.
    Taira R, Satake M, Momose S, Hino S, Suzuki Y, Murokawa H, Uchida S, Tadokoro K.
    Transfusion; 2013 Jul 02; 53(7):1393-404. PubMed ID: 23033944
    [Abstract] [Full Text] [Related]

  • 16. Hepatitis B virus nucleic acid amplification testing of Australian blood donors highlights the complexity of confirming occult hepatitis B virus infection.
    Kiely P, Margaritis AR, Seed CR, Yang H, Australian Red Cross Blood Service NAT Study Group.
    Transfusion; 2014 Aug 02; 54(8):2084-91. PubMed ID: 24650170
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of hepatitis B virus (HBV) DNA screening and characterization of acute and occult HBV infections among blood donors from Madrid, Spain.
    González R, Torres P, Castro E, Barbolla L, Candotti D, Koppelman M, Zaaijer HL, Lelie N, Allain JP, Echevarría JM.
    Transfusion; 2010 Jan 02; 50(1):221-30. PubMed ID: 19682332
    [Abstract] [Full Text] [Related]

  • 18. Prevalence, incidence and residual risk of transfusion-transmitted HBV infection before and after the implementation of HBV-NAT in northern Brazil.
    Corrêa ASM, Lamarão LM, Vieira PCM, de Castro RBH, de Almeida NCC, de Castro JAA, de Lima MSM, Palmeira MK, Meireles ALLP, Burbano RR.
    PLoS One; 2018 Jan 02; 13(12):e0208414. PubMed ID: 30566494
    [Abstract] [Full Text] [Related]

  • 19. Anti-hepatitis B core antigen testing with detection and characterization of occult hepatitis B virus by an in-house nucleic acid testing among blood donors in Behrampur, Ganjam, Orissa in southeastern India: implications for transfusion.
    Panigrahi R, Biswas A, Datta S, Banerjee A, Chandra PK, Mahapatra PK, Patnaik B, Chakrabarti S, Chakravarty R.
    Virol J; 2010 Aug 27; 7():204. PubMed ID: 20799931
    [Abstract] [Full Text] [Related]

  • 20. Occult hepatitis B virus infection: implications in transfusion.
    Allain JP.
    Vox Sang; 2004 Feb 27; 86(2):83-91. PubMed ID: 15023176
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.